http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
유영훈,송병정,백현문,이재연,정성미,황시영,정에벤,Sudeep Pradhan,윤휘열,권광일 충남대학교 약학대학 의약품개발연구소 2016 藥學論文集 Vol.31 No.-
Getting the spotlight to traditional medicine recently, the number of adverse effect and drug-drug interaction of traditional medicine is increased. For this reason, pharmacokinetics study of traditional medicine need to scientific prove of safety and effectiveness. The method of pharmacokinetics study of traditional medicine, Botanical drug guideline of U.S. FDA recommend to measure analytical marker concentration in blood. The aim of this study is quantitative content analysis of analytical marker in citrus unshiu peel for help pharmacokinetics study of traditional medicine. We seleceted naringin, naringenin, hesperidin and hesperetin as analytical marker and used HPLC-MS/MS as analysis equipment. Internal standard (IS) is domperidone. The mass transition of hesperidin, hesperetin, naringin and naringenin were 609.4 → 300.9, 301.0 → 285.8, 579.23 → 270.9 and 271.0 → 150.8 respectively. The result of this study is that 1g citrus unshiu peel has 12.24 mg (1.224%) hesperidin, 0.66 mg (0.066%) hesperetin, 15.17 mg (1.517%) naringin, and naringenin was not detected. citrus unshiu peel analytical marker that we can detect is naringin, naringenin, hesperidin. We could confirmed amount of citrus unshiu peel analytical marker through this study and our data further support the pharmacokinetics study of traditional medicine.
SD-rat에 KIOM-MA128을 경구 투여 한 후 혈장 중 Matrine의 약물 동태
이재연(Jae-yeon Lee),정성미(Seong Mee Jung),채정우(Jung-woo Chae),송병정(Byungjeong Song),백현문(Hyun-moon Back),윤휘열(Hwi-yeol Yun),권광일(Kwang-il Kwon),Sudeep Pradhan 大韓藥學會 2015 약학회지 Vol.59 No.3
KIOM-MA128 is a novel Korean herbal medicine with anti-atopic, anti-inflammatory and anti-asthmatic effects. This article presents the first pharmacokinetic study on KIOM-MA128. The purpose of this study was to characterize a pharmacokinetic characteristic of matrine, a potential marker of KIOM-MA128, in rats using population pharmacokinetic model. 1, 2 and 8 g/kg of KIOM-MA128 were administered to rats orally and plasma concentrations of matrine was determined by HPLC-MS/MS. Non-compartmental analysis (NCA) was performed using Phoenix?? and pharmacokinetic model was built using NONMEM??. This model was validated with internal validation which is visual predictive check (VPC) and bootstrap. The NCA result of matrine showed that Cmax was 294.24, 552.22 and 868.65 ng/ml, AUCinf was 1273.05, 2724.76 and 9743.25 ng · hr/ml and Tmax was 1, 1.3 and 2.3 hr for the doses of 1, 2, and 8 g/kg, respectively. The rat plasma concentrations were described very well with one-compartment model. Pharmacokinetic model for matrine was successfully developed and evaluated. Finally, our model is helpful to understand pharmacokinetic characteristic of KIOM-MA128.